TUSTIN, CA--(Marketwire - January 19, 2011) - Radient Pharmaceuticals Corporation (NYSE Amex: RPC), a US-based company specializing in the research, development, and international commercialization of In Vitro Diagnostic cancer tests, announced today it has been selected to present at the 8th Annual BIO Asia International Partnering Conference January 24-25, 2010 in Tokyo, Japan. Hosted by the Biotechnology Industry Organization (BIO), this exclusive event brings together U.S. and European healthcare and pharmaceutical companies with Asian biotech and pharmaceutical companies interested in research and development collaborations and licensing and distribution agreements.
Recognized as the premier biotech business development event in Asia, the BIO Asia International Partnering Conference brings together a diverse international audience composed of senior-level executives and business development decision makers from more than 325 companies located in over 25 countries, including both emerging Companies like Radient Pharmaceuticals, and industry leaders like Abbott Labs, Amgen, Baxter, Eli Lilly, AstraZeneca and Sanofi Aventis. In addition to intimate networking sessions, attendees have unparalleled exposure to both emerging and established companies seeking strategic partnerships, licensing and business collaboration opportunities, and complete access to educational and plenary sessions, corporate presentations, and private, pre-arranged one-on-one meetings.
According to Radient Pharmaceuticals Chairman and CEO Douglas MacLellan, “We are extremely pleased to be selected as a presenter in this exclusive partnering forum and look forward to introducing RPC and our FDA-cleared Onko-Sure® In Vitro Diagnostic (IVD) cancer test to select companies that represent strategic alliance, partnership and investment opportunities for our business. Events of this caliber are part of our on-going commercialization efforts for Onko-Sure® and offer an excellent venue to network with key members of the healthcare community -- both on the business and research and science side, who can help us advance and grow RPC for the long-term value of our shareholders.”
RPC’s Onko-Sure® IVD cancer test is a simple, non-invasive and regulatory-approved in vitro diagnostic (IVD) test used for the detection and monitoring of the treatment and/or recurrence of various types of cancer. The test enables physicians and healthcare professionals to effectively detect and/or monitor certain types of cancers by measuring the accumulation of Fibrin and Fibrinogen Degradation Products (FDP) in the blood. FDP levels rise dramatically with the progression of cancer. Onko-Sure® is cleared by the US FDA for detection during colorectal cancer treatment and/or for recurrence monitoring in colorectal cancer patients and by Health Canada for the detection, treatment and/or recurrence monitoring of lung cancer. For more information visit www.onko-sure.com.
About BIO
BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtech Now, an online portal and monthly newsletter chronicling ‘innovations transforming our world.’
About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® Test Kits for colon-rectal cancer recurrence monitoring. The company’s focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease-state detection, treatment strategy, and the monitoring of disease progression or recurrence. To learn more about our company, products, and potentially life-saving cancer test, visit www.radient-pharma.com.
For additional information on Radient Pharmaceuticals Corporation and its products visit: www.radient-pharma.com or send e-mail to info@radient-pharma.com. For Investor Relations contact Kristine Szarkowitz at IR@RadientPharma.com or 1.206.310.5323.
Forward-Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.
RPC Contact:
Kristine Szarkowitz
Director-Investor Relations
Email Contact
(Tel : ) 206.310.5323
Digg this
Bookmark with del.icio.us
Add to Newsvine
Technorati: 
